{
    "nct_id": "NCT06579196",
    "official_title": "Evaluation of Trabedersen (OT-101) With Pembrolizumab in Patients With Newly Diagnosed Advanced Non-Small Cell Lung Cancer and Positive PD-L1",
    "inclusion_criteria": "* Age ≥ 19 years\n* Histologically/cytologically proven diagnosis of non-small cell lung cancer (NSCLC) with a PD-L1 of at least 1%\n* Metastatic disease or disease not amenable for curative intent therapy\n* No prior treatment for metastatic NSCLC. Early-stage disease therapy acceptable if completed at least six months prior and did not include immunotherapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Measurable disease by RECIST criteria\n* Adequate organ and marrow function as defined below:\n\n  * Absolute neutrophil count ≥1,500/mm3\n  * Platelets ≥100,000/mm3\n  * Hemoglobin >9.0 mg/dL\n  * Creatinine clearance > 60 ml/min/1.73 m2 using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula\n  * Total serum bilirubin <1.5 X upper limit of normal (ULN) except if known to have Gilbert's syndrome, then excluded if total bilirubin >2.5 X ULN\n  * Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) ≤ 2.5 x ULN; if participant has liver metastases, ≤5x ULN\n* For females of childbearing potential, negative serum or urine pregnancy test ≤7 days of treatment, & agree to use effective contraceptive during treatment & 90 days after end of treatment\n* Male participants must agree to use effective contraception during the trial & for 90 days after end of treatment\n* Able to give informed consent\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Received any systemic treatments including investigational agents within the last 28 days\n* Known hypersensitivity to any of the excipients of OT101 or pembrolizumab\n* Received radiotherapy within 14 days of the study intervention. Palliative radiation is allowed during the study with a 1-week washout\n* Pregnant or breast-feeding women\n* History of autoimmune diseases that required systemic treatment in the past 2 years with agents such as, but not limited to, corticosteroids or immunosuppressive drugs. Thyroid replacement for hypothyroidism, insulin treatment for type I diabetes or corticosteroids adrenal/pituitary insufficiency are allowed.\n* Uncontrolled systemic diseases that in the opinion of the investigator may interfere with the protocol activities\n* Known active second malignancy that needs treatment. Exceptions include basal cell or squamous cancers of the skin, bladder or cervical carcinoma in situ, prostate cancer on hormone therapy alone.\n* Immunodeficiency diagnosis or receiving chronic steroids that exceed a dose equivalent to prednisone 10 mg daily\n* Symptomatic brain metastases. Asymptomatic metastases or having received treatment for brain metastases and are off steroid therapy is acceptable.\n* Known psychiatric or substance use that would interfere with the study requirements\n* Inability to co-operate with the requirements of the protocol",
    "miscellaneous_criteria": ""
}